NCT00289016View on ClinicalTrials.gov

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

May 31, 2009

Conditions
Melanoma
Interventions
DRUG

Talimogene Laherparepvec

Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection

Trial Locations (8)

10032

Columbia University, Department of Surgery, New York

55422

Hubert H Humphrey Cancer Center, Robbinsdale

75246

Mary Crowely Medical Research Center, Dallas

80010

University of Colorado, Anschutz Cancer Pavillion, Aurora

90095

UCLA, Los Angeles

92093

UCSD Cancer Center, Thornton Hospital, La Jolla

07042

Mountainside Hospital, Montclair

SW3 6JJ

Royal Marsden Hospital, London

All Listed Sponsors
collaborator

Symbion Research International

INDUSTRY

lead

BioVex Limited

INDUSTRY

NCT00289016 - A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma | Biotech Hunter | Biotech Hunter